Matches in SemOpenAlex for { <https://semopenalex.org/work/W2474766430> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2474766430 abstract "The efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors have been studied worldwide. However, there are few reports directly comparing the efficacy and safety between icotinib and docetaxel as second-line treatment in lung adenocarcinoma patients who have failed platinum-based chemotherapy. This article offers insight into this field.A total of 137 patients with stage III or IV lung adenocarcinoma who had progressed on first-line platinum-based therapies and received icotinib or docetaxel therapy between October 2011 and February 2013 were retrospectively reviewed. Patients in the icotinib group received oral icotinib at a dose of 125 mg tid, while patients in the docetaxel group received infusion docetaxel at a dose of 75 mg/m(2) on day 1 of every 21 days (four to six cycles) until disease progression or unacceptable toxicity occurred after which best supportive care was given.There was no statistically significant difference in the objective response rate (23.3% vs 12.5%, P=0.103), progression-free survival (121 days vs 106 days, P=0.083), and overall survival (307 days vs 254 days, P=0.070) between the two groups. As compared to the docetaxel group, the disease control rate (75.3% vs 54.7%, P=0.011) was significantly better in the icotinib group. In the icotinib group, the most common adverse events were rash (35.62%) and diarrhea (24.66%), whereas in the docetaxel group, elevation of transaminase (37.50%), leukopenia (50.00%), and anemia (54.69%) were the most common.Icotinib had similar efficacy and a lower adverse events rate in epidermal growth factor receptor-unselected patients as compared to docetaxel, thereby making it an effective second-line therapy option for lung adenocarcinoma." @default.
- W2474766430 created "2016-07-22" @default.
- W2474766430 creator A5007051998 @default.
- W2474766430 creator A5022938518 @default.
- W2474766430 creator A5034574898 @default.
- W2474766430 creator A5083111185 @default.
- W2474766430 creator A5087287319 @default.
- W2474766430 date "2016-07-01" @default.
- W2474766430 modified "2023-09-26" @default.
- W2474766430 title "Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study" @default.
- W2474766430 cites W1571650151 @default.
- W2474766430 cites W1979538859 @default.
- W2474766430 cites W1988106671 @default.
- W2474766430 cites W2020600748 @default.
- W2474766430 cites W2037791152 @default.
- W2474766430 cites W2040935952 @default.
- W2474766430 cites W2051676630 @default.
- W2474766430 cites W2057280411 @default.
- W2474766430 cites W2097026987 @default.
- W2474766430 cites W2099180737 @default.
- W2474766430 cites W2103250029 @default.
- W2474766430 cites W2111662961 @default.
- W2474766430 cites W2118548009 @default.
- W2474766430 cites W2122553809 @default.
- W2474766430 cites W2153942353 @default.
- W2474766430 cites W2158734599 @default.
- W2474766430 cites W2170552969 @default.
- W2474766430 doi "https://doi.org/10.2147/ott.s99434" @default.
- W2474766430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4936811" @default.
- W2474766430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27445494" @default.
- W2474766430 hasPublicationYear "2016" @default.
- W2474766430 type Work @default.
- W2474766430 sameAs 2474766430 @default.
- W2474766430 citedByCount "0" @default.
- W2474766430 crossrefType "journal-article" @default.
- W2474766430 hasAuthorship W2474766430A5007051998 @default.
- W2474766430 hasAuthorship W2474766430A5022938518 @default.
- W2474766430 hasAuthorship W2474766430A5034574898 @default.
- W2474766430 hasAuthorship W2474766430A5083111185 @default.
- W2474766430 hasAuthorship W2474766430A5087287319 @default.
- W2474766430 hasBestOaLocation W24747664301 @default.
- W2474766430 hasConcept C121608353 @default.
- W2474766430 hasConcept C126322002 @default.
- W2474766430 hasConcept C141071460 @default.
- W2474766430 hasConcept C143998085 @default.
- W2474766430 hasConcept C197934379 @default.
- W2474766430 hasConcept C2776694085 @default.
- W2474766430 hasConcept C2777063308 @default.
- W2474766430 hasConcept C2778570526 @default.
- W2474766430 hasConcept C2780873365 @default.
- W2474766430 hasConcept C2781182431 @default.
- W2474766430 hasConcept C2781190966 @default.
- W2474766430 hasConcept C71924100 @default.
- W2474766430 hasConcept C90924648 @default.
- W2474766430 hasConceptScore W2474766430C121608353 @default.
- W2474766430 hasConceptScore W2474766430C126322002 @default.
- W2474766430 hasConceptScore W2474766430C141071460 @default.
- W2474766430 hasConceptScore W2474766430C143998085 @default.
- W2474766430 hasConceptScore W2474766430C197934379 @default.
- W2474766430 hasConceptScore W2474766430C2776694085 @default.
- W2474766430 hasConceptScore W2474766430C2777063308 @default.
- W2474766430 hasConceptScore W2474766430C2778570526 @default.
- W2474766430 hasConceptScore W2474766430C2780873365 @default.
- W2474766430 hasConceptScore W2474766430C2781182431 @default.
- W2474766430 hasConceptScore W2474766430C2781190966 @default.
- W2474766430 hasConceptScore W2474766430C71924100 @default.
- W2474766430 hasConceptScore W2474766430C90924648 @default.
- W2474766430 hasLocation W24747664301 @default.
- W2474766430 hasLocation W24747664302 @default.
- W2474766430 hasLocation W24747664303 @default.
- W2474766430 hasLocation W24747664304 @default.
- W2474766430 hasOpenAccess W2474766430 @default.
- W2474766430 hasPrimaryLocation W24747664301 @default.
- W2474766430 isParatext "false" @default.
- W2474766430 isRetracted "false" @default.
- W2474766430 magId "2474766430" @default.
- W2474766430 workType "article" @default.